Call for Paper - January 2023 Edition
IJCA solicits original research papers for the January 2023 Edition. Last date of manuscript submission is December 20, 2022. Read More

Docking Studies reveal Phytochemicals as the long searched Anticancer Drugs for Breast Cancer

International Journal of Computer Applications
© 2013 by IJCA Journal
Volume 67 - Number 25
Year of Publication: 2013
Saba Ferdous
Muhammad Usman Mirza
Usman Saeed

Saba Ferdous, Muhammad Usman Mirza and Usman Saeed. Article: Docking Studies reveal Phytochemicals as the long searched Anticancer Drugs for Breast Cancer. International Journal of Computer Applications 67(25):1-5, April 2013. Full text available. BibTeX

	author = {Saba Ferdous and Muhammad Usman Mirza and Usman Saeed},
	title = {Article: Docking Studies reveal Phytochemicals as the long searched Anticancer Drugs for Breast Cancer},
	journal = {International Journal of Computer Applications},
	year = {2013},
	volume = {67},
	number = {25},
	pages = {1-5},
	month = {April},
	note = {Full text available}


Natural products including phytochemicals have been recently proposed as tumor suppressors. In this paper, docking study is presented to use these phytochemicals for their prospective role in cancers including breast and prostate cancer. The most common type of cancer in women all over the world is breast cancer. The breast cells including cancerous breast cells have receptors for binding with estrogen and progesterone to stimulate a growth response. This crucial property has been exploited to investigate binding properties of phytochemicals with these receptors to generate an antagonist response in order to resolve uncontrolled cancerous growth. The most commonly used breast cancer drugs mainly work against the effects of estrogen on these cells. In this context groups of different set of phytochemicals (3-IMG-Glucosinolates, Anthocyanins, Apigenin, Carnosol, Daidzein, Genistein, Isoflavones and Quercetin) were taken and docked into the active site of Human estrogen receptor (PDB ID: 2IOK). In this study, based on molecular docking, potential phytochemicals have successfully been identified which may be used as anticancer drugs against breast cancer. These studies based on binding energy, docking energy, drug likeness and other relevant scores show that Daidzein, Genistein and Quercetin could be the potential lead molecule for the inhibition of signals potent for Human breast cancer and Leu346, Leu384, Leu387, Phe404 and Leu525 are the most important residues for potential drug targets. This paper is the initial step towards a rational design of novel selective and potent Human estrogen inhibitors for the treatment of cancer.


  • Medchem designer. http://www. simulations-plus. com/Products. aspx?grpID=1&cID=20&pID=25. Accessed: 19/02/2013.
  • World health organization international agency for research on cancer. World Cancer Report, June 2008.
  • Herman Adlercreutz. Phytoestrogens and breast cancer. The Journal of steroid biochemistry and molecular biology, 83(1):113–118, 2002.
  • Aedin Cassidy, Bryan Hanley, and Rosa M Lamuela- Raventos. Isoflavones, lignans and stilbenes–origins, metabolism and potential importance to human health. Journal of the Science of Food and Agriculture, 80(7):1044–1062, 2000.
  • John C Dearden. In silico prediction of admet properties: how far have we come? 2007.
  • Joe Dundas, Zheng Ouyang, Jeffery Tseng, Andrew Binkowski, Yaron Turpaz, and Jie Liang. Castp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic acids research, 34(suppl 2):W116–W118, 2006.
  • K. D. Dykstra, L. Guo, E. T. Birzin, W. Chan, Y. T. Yang, E. C. Hayes, C. A. DaSilva, L. Y. Pai, R. T. Mosley, B. Kraker, P. M. Fitzgerald, F. DiNinno, S. P. Rohrer, J. M. Schaeffer, and M. L. Hammond. Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ERalpha. Bioorg. Med. Chem. Lett. , 17(8):2322–2328, Apr 2007.
  • Mark A Espeland, Sally A Shumaker, Marian Limacher, Stephen R Rapp, Therese B Bevers, David H Barad, Laura H Coker, Sarah A Gaussoin, Marcia L Stefanick, Dorothy S Lane, et al. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. Journal of Women's Health, 19(3):371–379, 2010.
  • Alasdair TR Laurie and Richard M Jackson. Q-sitefinder: an energy-based method for the prediction of protein– ligand binding sites. Bioinformatics, 21(9):1908–1916, 2005.
  • J. C. Le Bail, Y. Champavier, A. J. Chulia, and G. Habrioux. Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci. , 66(14):1281–1291, Feb 2000.
  • Christopher A Lipinski, Franco Lombardo, Beryl W Dominy, and Paul J Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 2012.
  • Roy Ackermann Michelle Harvie. Genesis breast cancer prevention diet. pages 113–114, 2006.
  • Shoko Morishima, Masa-Aki Shibata, Masahide Ohmichi, and Yoshinori Otsuki. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells. Medical molecular morphology, 41(3):132–138, 2008.
  • Garrett M Morris, Ruth Huey, William Lindstrom, Michel F Sanner, Richard K Belew, David S Goodsell, and Arthur J Olson. Autodock4 and autodocktools4: Automated docking with selective receptor flexibility. Journal of computational chemistry, 30(16):2785–2791, 2009.
  • Eric F Pettersen, Thomas D Goddard, Conrad C Huang, Gregory S Couch, Daniel M Greenblatt, Elaine C Meng, and Thomas E Ferrin. Ucsf chimeraa visualization system for exploratory research and analysis. Journal of computational chemistry, 25(13):1605–1612, 2004.
  • Maria Russo, Carmela Spagnuolo, Idolo Tedesco, and Gian Luigi Russo. Phytochemicals in cancer prevention and therapy: Truth or dare? Toxins, 2(4):517–551, 2010.
  • Kenneth DR Setchell and Aedin Cassidy. Dietary isoflavones: biological effects and relevance to human health. The journal of nutrition, 129(3):758S–767S, 1999.
  • Snait Tamir, Mark Eizenberg, Dalia Somjen, Naftali Stern, Rayah Shelach, Alvin Kaye, and Jacob Vaya. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer research, 60(20):5704– 5709, 2000.
  • Junmei Wang, Wei Wang, Peter A Kollman, and David A Case. Automatic atom type and bond type perception in molecular mechanical calculations. Journal of molecular graphics and modelling, 25(2):247–260, 2006.
  • YanliWang, Evan Bolton, Svetlana Dracheva, Karen Karapetyan, Benjamin A Shoemaker, Tugba O Suzek, Jiyao Wang, Jewen Xiao, Jian Zhang, and Stephen H Bryant. An overview of the pubchem bioassay resource. Nucleic acids research, 38(suppl 1):D255–D266, 2010.
  • Caroline JWitton, Jonathan R Reeves, James J Going, Timothy G Cooke, and John Bartlett. Expression of the her1–4 family of receptor tyrosine kinases in breast cancer. The Journal of pathology, 200(3):290–297, 2003.
  • Rachel S Rosenberg Zand, David JA Jenkins, and Eleftherios P Diamandis. Steroid hormone activity of flavonoids and related compounds. Breast cancer research and treatment, 62(1):35–49, 2000.